PI3K Signaling Pathways as a Molecular Target for Glioblastoma Multiforme.

IF 1.9 4区生物学 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY Current protein & peptide science Pub Date : 2024-01-01 DOI:10.2174/1389203724666230830125102

Andressa Letícia Lopes da Silva, Thiago Pina Goes de Araújo, Shakira Cavalcante de Albuquerque Ferreira, Anderson Brandão Leite, João Kaycke Sarmento da Silva, Lilyana Waleska Nunes Albuquerque, Ana Rachel Vasconcelos de Lima, Herbert Charles Silva Barros, Leandro Rocha Silva, Edeildo Ferreira da Silva-Júnior, João Xavier de Araújo-Júnior, Vivaldo Moura Neto, Aline Cavalcanti de Queiroz, Magna Suzana Alexandre-Moreira

{"title":"PI3K Signaling Pathways as a Molecular Target for Glioblastoma Multiforme.","authors":"Andressa Letícia Lopes da Silva, Thiago Pina Goes de Araújo, Shakira Cavalcante de Albuquerque Ferreira, Anderson Brandão Leite, João Kaycke Sarmento da Silva, Lilyana Waleska Nunes Albuquerque, Ana Rachel Vasconcelos de Lima, Herbert Charles Silva Barros, Leandro Rocha Silva, Edeildo Ferreira da Silva-Júnior, João Xavier de Araújo-Júnior, Vivaldo Moura Neto, Aline Cavalcanti de Queiroz, Magna Suzana Alexandre-Moreira","doi":"10.2174/1389203724666230830125102","DOIUrl":null,"url":null,"abstract":"<p><p>Glioblastoma multiforme (GBM) is the most common type of cancer that affects the central nervous system (CNS). It currently accounts for about 2% of diagnosed malignant tumors worldwide, with 296,000 new cases reported per year. The first-choice treatment consists of surgical resection, radiotherapy, and adjuvant chemotherapy, which increases patients' survival by 15 months. New clinical and pre-clinical research aims to improve this prognosis by proposing the search for new drugs that effectively eliminate cancer cells, circumventing problems such as resistance to treatment. One of the promising therapeutic strategies in the treatment of GBM is the inhibition of the phosphatidylinositol 3-kinase (PI3K) pathway, which is closely related to the process of tumor carcinogenesis. This review sought to address the main scientific studies of synthetic or natural drug prototypes that target specific therapy co-directed via the PI3K pathway, against human glioblastoma.</p>","PeriodicalId":10859,"journal":{"name":"Current protein & peptide science","volume":" ","pages":"12-26"},"PeriodicalIF":1.9000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current protein & peptide science","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.2174/1389203724666230830125102","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Glioblastoma multiforme (GBM) is the most common type of cancer that affects the central nervous system (CNS). It currently accounts for about 2% of diagnosed malignant tumors worldwide, with 296,000 new cases reported per year. The first-choice treatment consists of surgical resection, radiotherapy, and adjuvant chemotherapy, which increases patients' survival by 15 months. New clinical and pre-clinical research aims to improve this prognosis by proposing the search for new drugs that effectively eliminate cancer cells, circumventing problems such as resistance to treatment. One of the promising therapeutic strategies in the treatment of GBM is the inhibition of the phosphatidylinositol 3-kinase (PI3K) pathway, which is closely related to the process of tumor carcinogenesis. This review sought to address the main scientific studies of synthetic or natural drug prototypes that target specific therapy co-directed via the PI3K pathway, against human glioblastoma.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

作为多形性胶质母细胞瘤分子靶点的 PI3K 信号通路

多形性胶质母细胞瘤（GBM）是影响中枢神经系统（CNS）的最常见癌症类型。目前，它约占全球确诊恶性肿瘤的 2%，每年新增病例 29.6 万例。首选治疗方法包括手术切除、放射治疗和辅助化疗，可使患者的生存期延长 15 个月。新的临床和临床前研究旨在通过寻找能有效消灭癌细胞的新药来改善预后，从而避免耐药性等问题。抑制与肿瘤发生过程密切相关的磷脂酰肌醇 3- 激酶（PI3K）通路是治疗 GBM 的有前途的治疗策略之一。本综述试图探讨通过 PI3K 通路共同引导的针对人类胶质母细胞瘤特定疗法的合成或天然药物原型的主要科学研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current protein & peptide science 生物-生化与分子生物学

CiteScore

5.20

自引率

0.00%

发文量

审稿时长

6 months

期刊介绍： Current Protein & Peptide Science publishes full-length/mini review articles on specific aspects involving proteins, peptides, and interactions between the enzymes, the binding interactions of hormones and their receptors; the properties of transcription factors and other molecules that regulate gene expression; the reactions leading to the immune response; the process of signal transduction; the structure and function of proteins involved in the cytoskeleton and molecular motors; the properties of membrane channels and transporters; and the generation and storage of metabolic energy. In addition, reviews of experimental studies of protein folding and design are given special emphasis. Manuscripts submitted to Current Protein and Peptide Science should cover a field by discussing research from the leading laboratories in a field and should pose questions for future studies. Original papers, research articles and letter articles/short communications are not considered for publication in Current Protein & Peptide Science.